ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
L1 Childhood Acute Lymphoblastic Leukemia
Therapeutic Advances in Childhood Leukemia Consortiumprotein_peptidePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the L1 Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
ASPARAGINASE Therapeutic Advances in Childhood Leukemia Consortium | Phase 3 | BBB |
PREDNISONE TABLETS Therapeutic Advances in Childhood Leukemia Consortium | Phase 3 | BBB |
Allopurinol Vastra Gotaland Region | Phase 2 | B |
aciclovir National Cancer Institute (NCI) | Phase 1/2 | CCC |
Same molecule, other indications
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →